12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...

Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...

Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...